|
|
|
市場調查報告書
全球RNA干擾（RNAi）市場
RNA interference (RNAi)
|
本報告已在2012年05月14日停止出版。
更改為出版
RNA Interference (RNAi)
出版日期 : 2012年04月
商品編碼: 240220
本報告為，調查全球RNA干擾（RNAi）市場，並匯整RNAi產品概要、產品開發及臨床實驗、法規趨勢、市場參與企業、全球各國地區別趨勢等，以下列摘要形式闡述。
第1章 序、調查方式及範圍
第2章 產業展望
第3章 產業概要
第4章 市場展望
- 具潛力之寡核苷酸技術
- 與siRNA競爭之寡核苷酸類概要
- 寡核苷酸市場可承受不景氣打擊
- 產品線之RNAi治療藥物：2009年目前
- 新等級之RNAi藥劑
- 帶動RNAi市場成長之RNAi類治療藥物
- 疾病統計學
- 治療藥物之RNAi
- 年齡相關性黃斑變性
- 產品線中具可行性之RNAi藥劑，其他
第5章 產品概要
- RNA干擾之歷史
- RNAi途徑
- 其他仲介RNA干擾之sRNA
第6章 RNA干擾之應用
- RNA干擾之重要性
- 應用領域
- RNAi應用領域回顧
第7章 法規許可
第8章 技術床新
第9章 近來產業趨勢
第10章 主要企業
- Alnylam Pharmaceuticals, Inc.
- Benitec Limited
- Bioneer Corp.
- Calando Pharmaceuticals, Inc.
- Cenix BioScience GmbH
- Devgen NV
- Dharmacon, Inc.
- Dicerna Pharmaceuticals, Inc.
- Exiqon A/S
- Genesis Research & Development Corporation Limited
- Halo-Bio RNAi Therapeutics, Inc.
- Marina Biotech, Inc.
- OPKO Health, Inc.
- Polyplus-transfection S
- Quark Pharmaceuticals, Inc.
- RXi Pharmaceuticals Corp.
- Sigma-Aldrich Co.
- Silence Therapeutics
- Tekmira Pharmaceuticals Corp.
第11章 全球市場展望
第12章 美國
第13章 加拿大
第14章 日本
第15章 歐洲
第16章 亞太地區
第17章 其他地區
介紹企業數：136間
Abstract
This report analyzes the worldwide markets for RNA interference (RNAi) in US$
Million by the following application areas: Drug Discovery and Target
Validation, Reagents, and siRNA Synthesis. The report provides separate
comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and
Rest of World. Annual estimates and forecasts are provided for the period
2009 through 2017. Also, a six-year historic analysis is provided for these
markets. The report profiles 136 companies including many key and niche
players such as Alnylam Pharmaceuticals, Inc., Benitec Limited, Bioneer Corp.,
Calando Pharmaceuticals, Inc., Cenix BioScience GmbH, Devgen NV, Dharmacon,
Inc., Dicerna Pharmaceuticals, Inc., Exiqon A/S, Genesis Research &
Development Corporation Limited, Halo-Bio RNAi Therapeutics, Inc., Marina
Biotech, Inc., OPKO Health, Inc., Polyplus-transfection SA, Quark
Pharmaceuticals, Inc., RXi Pharmaceuticals Corp., Sigma-Aldrich Co., Silence
Therapeutics, and Tekmira Pharmaceuticals Corp. Market data and analytics are
derived from primary and secondary research. Company profiles are mostly
extracted from URL research and reported select online sources.
Table of Contents
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- Product Segments
- Drug Discovery and Target Validation
- Reagents
- SiRNA Synthesis
2. INDUSTRY OUTLOOK
- RNA Interference: A Historic Perspective
3. INDUSTRY OVERVIEW
- Leading Regional Markets
- High-throughput Screening: A Promising Application for RNA Interference
- Growth Drivers
4. MARKET OUTLOOK
- RNA Interference: A Potential Oligonucleotide Technology
- A Review of Select Classes of Oligonucleotides Competing with siRNA
- Oligonucleotide Market Sustains Recession
- Select RNAi-based Therapeutics in the Pipeline: As of 2009
- RNAi: A Leading Research Tool in Gene-Silencing
- RNAi-based Drugs to Emerge as a New Class of Therapeutics
- RNAi-based Therapeutics to Drive the Growth of RNAi Market
- Statistics on Select Diseases
- Cancer
- Table 1: Global Cancer Incidence by Region: 2009 (includes
corresponding Graph/Chart)
- Table 2: Global Cancer Incidence by Country: 2009 (includes
corresponding Graph/Chart)
- Table 3: Global Cancer Incidence by Income Group: 2009 (includes
corresponding Graph/Chart)
- Table 4: Global Cancer Related Deaths in Male Population by Site:
2007 (includes corresponding Graph/Chart)
- Table 5: Global Cancer Related Deaths in Female Population by Site:
2007(includes corresponding Graph/Chart)
- Cardiovascular Diseases
- Table 6: Global Coronary Heart Disease Prevalence by Region
(includes corresponding Graph/Chart)
- Table 7: Deaths Due to Major Cardiovascular Diseases in the US:
Percentage Share Breakdown by Disease Type (includes corresponding
Graph/Chart)
- Huntington' s Disease (HD)
- Diabetic Retinopathy
- Table 8: Diabetic Retinopathy Patient Prevalence in the US by
Diabetes Type: 2006-2015 (In Thousand Patients) (includes corresponding
Graph/Chart)
- Table 9: Diabetic Retinopathy Patient Prevalence in the US by Age
Group: 2006-2012 (includes corresponding Graph/Chart)
- Table 10: Diabetic Retinopathy Prevalence in Type-1 Diabetic
Patients in the US by Age Group: 2006-2012 (includes corresponding
Graph/Chart)
- RNAi in Drug Therapeutics
- RNAi: Select Targeted Clinical Areas
- Age Related Macular Degeneration: A Key Clinical Area of Focus
- Select Promising RNAi Drugs in Pipeline: A Review
- ALN-VSP
- Atu027
- CALAA-01
- CEQ501
- RNAi Therapeutics: Challenges in a Nutshell
- Drug Delivery: A Key Challenge Facing RNAi-based Therapeutics
- Select Methods of Systemic Drug Delivery under Development
- Select RNAi Drug Delivery Technologies under Development
- Other Challenges Facing RNAi-based Therapeutics
- A Snapshot of Select RNAi Delivery Platforms Under Development
- Lipid Nanoparticle (LNP) siRNA Delivery Technology Platform (Tekmira)
- RONDEL (Calando Pharmaceuticals)
- Lipid and Polymer Based Delivery Platforms (Silence Therapeutics)
- AtuPlex/AtuFect Delivery Platform
- PolyTrantrade; Delivery Platform
- RNAi Nanoplex Delivery Technology (Intradigm Corporation)
- DiLA2 Platform (Marina Biotech)
5. PRODUCT OVERVIEW
- History of RNA Interference
- Co-Suppression and Quelling
- VIGS (Virus Induced Gene Suppression)
- RNA Interference or Post Transcriptional Silencing
- The RNAi Pathway
- siRNA and miRNA
- RISC Complex
- Transfer and Heritance
- The Difference
- Other Short RNAs mediating RNA Interference
- Small Hairpin RNA (shRNA)
- Repeat associated small interfering RNA (rasiRNA)
- Comparison of Various Types of RNAs in RNA Interference
6. APPLICATIONS OF RNA INTERFERENCE
- Significance of RNA Interference
- Role of RNAi in Gene Silencing
- RNA Interference Affects Protein Synthesis at the Level of Translation
- Role of mRNA in Gene Expression
- RNAi: Application Areas
- RNAi in Drug Discovery and Target Validation
- RNAi in Functional Genomics
- Why RNAi over Other Techniques ?
- Use of RNAi in the Study of Functional Genomics in Humans
- Model Organisms and Off-target Effects
- Select Target Validation Systems
- RNAiMonitortrade; (Clontech Laboratories, Inc)
- GenoExplorertrade; microRNA System (GenoSensor Corp)
- RNAi Reagents
- Select RNAi Reagents and Transfection Kits
- Lipofectaminetrade; RNAiMAX Transfection Reagent (Invitrogen Life
Technologies)
- siGENOME® siRNA Reagents (Dharmacon RNA Technologies)
- ON-TARGETplustrade; SMARTpool Reagents (Dharmacon RNA Technologies)
- Vector-based RNAi Reagents (Thermo Scientific)
- siRNA transfection kits (Bio-Rad Lab)
- Fluorescent Reagents (OZ Biosciences)
- ICAFectintrade; 442 siRNA Transfection Reagent (Tekmira)
- TransIT®-mRNA Transfection Kit (Mirus Bio llc)
- siRNA Synthesis
- siRNA: A Popular Tool for the Detection and Induction of Gene Silencing
- Methods of siRNA Synthesis
- Select Synthetic siRNAs
- Synthetic siRNAs (Eurogentec SA)
- Ambion® In Vivo Pre-designed siRNAs (Applied Biosystems, Inc.)
- Silencer® Pre-Designed & Validated siRNAs (Applied
Biosystems, Inc.)
- HuSH-29: pre-designed shRNA (OriGene Technologies, Inc.)
- A Review of other Application Areas of RNAi
- RNAi in Agriculture and Plant Biotechnology
- miRNA as Biomarkers and Therapeutic Targets - An Insight
- miRNA: Clinical Areas under Focus
7. REGULATORY APPROVALS
- Asuragen Obtains Notices of Allowance for Several miRNA Patent
Applications
- Genable Technologies Obtains Orphan Designation by EMA
- Benitec Obtains RNA Interference Patent from EPO
- Silence Therapeutics Bags New Patent Rights
- Benitec Receives RNAi Related Patent Grant from USPTO
- Marina Obtains Notices of Allowance for siRNA Patent Applications
- USPTO Grants a RNAi Related Patent to Benitec
- Alnylam Receives Patent Rights for Woppmann Patent Series
- Kylin Bags Patent Rights for pRNAi Technology
- Allele Biotechnology Obtains Patent Approval for DNA-Encoded RNAi
- Silence Therapeutics Obtains Notices of Allowance for RNAi Patent
Applications
- RXi Obtains Notices of Allowance for siRNA Patent Applications
- Intradigm Obtains Patent for siRNA Sequence
- Intradigm Receives Key RNAi Patent Allowance
8. TECHNOLOGICAL INNOVATIONS
- Cellecta Introduces New Open Source Genome-Wide RNAi Screening Platform
- Tekmira, Alnylam, and UBC Co-Develop New Lipid Component
- ID Tech Introduces Improved miRCattrade; Small RNA Cloning System
- Integrated DNA Technologies Launches Transductintrade;
- Abnova Unveils New Gene Silencing Tool
- Polyplus-transfection Introduces jetPRIMEtrade; Transfection Reagent
- Sigma-Aldrich Launches Gene-Specific MISSION esiRNA
- CombiMatrix to Introduce miRNA Cancer-Screening Test in the US
- GeneCopoeia Unveils microRNA Tools and Reagents for Functional Analysis
- Invitrogen Introduces Invivofectaminetrade; Delivery Reagent
9. RECENT INDUSTRY ACTIVITY
- Cenix to Establish New Subsidiary
- Arrowhead Acquires Stake in US Subsidiary, Calando
- RXi and Generex Obtain Positive Research Data for Exploring RNAi
Technology
- Rosetta Obtains Permit for miRNA-based Diagnostics in NY
- Alnylam Pharmaceuticals Introduces Alnylam 5x15 Product Strategy
- Cenix BioScience Receives R&D Grant from Saxony
- Kyowa and Dicerna Expand Research Collaboration
- MDRNA Acquires BNA Intellectual Property from Valeant
- Sirnaomics Partners with a Chinese Company for RNAi Therapeutics
Development
- Kylin Obtains IRS Grant for Advancing Research on pRNAi Nanoparticle
- Tekmira Obtains New License for Alnylam' s InterfeRxtrade;
- RXi to Collaborate with EyeGate
- Sigma Life Partners with SwitchGear Genomics for miRNA Validation System
- Marina Biotech Acquires Novosom' s SMARTICLES® Intellectual Property
Estate
- Quark to Collaborate with Nitto Denko for Co-Developing siRNA-based
Anti-fibrotic Drug
- AstraZeneca and Silence Therapeutics Extend R&D Alliance
- Silence Therapeutics and AstraZeneca Extend siRNA Delivery Partnership
- MDRNA to Take Over Cequent
- Traversa and sanofi-aventis Ink Research Agreement
- Pfizer to Develop HCV Compounds of Tacere Therapeutics
- Intradigm and Silence Therapeutics Merge
- Sirna Therapeutics and Allergan form Joint Drug Development Alliance
- Benitec Collaborates with CCIA
- RXi Pharmaceuticals Obtains Advirna' s RNAi Technology
- RXi Obtains Exclusive Licensing Rights to Advirna' s Delivery Technologies
- Dicerna Collaborates with Archemix
- Alnylam Collaborates with GSK to Donate Several RNAi Technology Patents
- AstraZeneca and Cenix Extend Research Agreement on RNA Interference
- Allergan Stops Development of AGN-745 Treatment
- Tekmira Inks Agreement with Roche
- MDRNA Inks Licensing Agreement with Novartis
- MDRNA Inks Agreement with Roche for Developing RNAi Therapeutics
- Mirna Therapeutics to Investigate Therapeutic Potential of miRNA
- Cenix and Boehringer Ingelheim Ink Research Agreement
- Mirna and M. D. Anderson to Explore miRNA Therapeutics in Prostate Cancer
- Cubist Partners with Alnylam Pharmaceuticals
- Liquidia to License Certain Rights of PRINT technology to Abbott
- Invitrogen Merges with Applied Biosystems
- MDRNA Obtains Rights to RiboTask' s UNA Technology
- Roche Takes Over Mirus
- Thermo Fischer Snaps Up Open Biosystems
- Protiva and Tekmira Complete the Merger of Business Operations
- Takeda and Alnylam Enter into Strategic Alliance
- SR Pharma Plc. is Now Silence Therapeutics Plc.
10. FOCUS ON SELECT PLAYERS
- Alnylam Pharmaceuticals, Inc. (USA)
- Benitec Limited (Australia)
- Bioneer Corp. (Korea)
- Calando Pharmaceuticals, Inc. (USA)
- Cenix BioScience GmbH (Germany)
- Devgen NV (Belgium)
- Dharmacon, Inc. (USA)
- Dicerna Pharmaceuticals, Inc. (USA)
- Exiqon A/S (Denmark)
- Genesis Research & Development Corporation Limited (New Zealand)
- Halo-Bio RNAi Therapeutics, Inc. (USA)
- Marina Biotech, Inc. (USA)
- OPKO Health, Inc. (USA)
- Polyplus-transfection SA (France)
- Quark Pharmaceuticals, Inc. (USA)
- RXi Pharmaceuticals Corp. (USA)
- Sigma-Aldrich Co. (USA)
- Silence Therapeutics (UK)
- Tekmira Pharmaceuticals Corp. (Canada)
11. GLOBAL MARKET PERSPECTIVE
- Table 11: World Recent Past, Current & Future Analysis for RNA
Interference Market by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes corresponding
Graph/Chart)
- Table 12: World Historic Review for RNA Interference Market by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart)
- Table 13: World 15-Year Perspective for RNA Interference Market by
Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2010 & 2017
(includes corresponding Graph/Chart)
- By Application Areas
- Table 14: World Recent Past, Current & Future Analysis for RNA
Interference in Drug Discovery and Target Validation Applications by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009
through 2017 (includes corresponding Graph/Chart)
- Table 15: World Historic Review for RNA Interference in Drug Discovery
and Target Validation Applications by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart)
- Table 16: World 15-Year Perspective for RNA Interference in Drug
Discovery and Target Validation Applications by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and
Rest of World for Years 2003, 2010 & 2017(includes corresponding
Graph/Chart)
- Table 17: World Recent Past, Current & Future Analysis for RNA
Interference Reagents by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes corresponding
Graph/Chart)
- Table 18: World Historic Review for RNA Interference Reagents by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart)
- Table 19: World 15-Year Perspective for RNA Interference Reagents by
Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2010 & 2017
(includes corresponding Graph/Chart)
- Table 20: World Recent Past, Current & Future Analysis for siRNA
Synthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and
Rest of World Independently Analyzed with Annual Sales Figures in US$ Million
for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 21: World Historic Review for siRNA Synthesis by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart)
- Table 22: World 15-Year Perspective for siRNA Synthesis by Geographic
Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific, and Rest of World for Years 2003, 2010 & 2017 (includes
corresponding Graph/Chart)
12. THE UNITED STATES
- A. Market Analysis
- Outlook
- Technological Innovations
- Cellecta Introduces New Open Source Genome-Wide RNAi Screening
Platform.
- ID Tech Introduces Improved miRCattrade; Small RNA Cloning System.
- Integrated DNA Technologies Launches Transductintrade;
- Sigma-Aldrich Launches Gene-Specific MISSION esiRNA
- CombiMatrix to Introduce miRNA Cancer-Screening Test in the US
- GeneCopoeia Unveils microRNA Tools and Reagents for Functional
Analysis
- Invitrogen Introduces Invivofectaminetrade; Delivery Reagent
- Strategic Corporate Developments
- Arrowhead Buys Stake in US Subsidiary, Calando
- RXi and Generex Obtain Positive Research Data for Exploring RNAi
Technology
- Rosetta Obtains Permit for miRNA-based Diagnostics in NY
- Alnylam Pharmaceuticals Introduces Alnylam 5x15 Product Strategy
- Kyowa and Dicerna Expand Research Collaboration
- MDRNA Buys BNA Intellectual Property from Valeant
- Kylin Obtains IRS Grant for Advancing Research on pRNAi Nanoparticle
- RXi to Collaborate with EyeGate
- MDRNA to Take Over Cequent
- Sirna Therapeutics and Allergan form Joint Drug Development Alliance
- RXi Pharmaceuticals Obtains Advirna' s RNAi Technology
- RXi Obtains Exclusive Licensing Rights to Advirna' s Delivery
Technologies
- Dicerna Collaborates with Archemix
- Alnylam Collaborates with GSK to Donate Several RNAi Technology
Patents
- Allergan Stops Development of AGN-745 Treatment
- MDRNA Inks Licensing Agreement with Novartis
- MDRNA Inks Agreement with Roche for Developing RNAi Therapeutics
- Mirna Therapeutics to Investigate Therapeutic Potential of miRNA
- Mirna and M. D. Anderson to Explore miRNA Therapeutics in Prostate
Cancer
- Cubist Partners with Alnylam Pharmaceuticals
- Invitrogen Merges with Applied Biosystems
- Roche Takes Over Mirus
- Thermo Fischer Snaps Up Open Biosystems
- Protiva and Tekmira Complete Merger of Business Operations
- Focus on Select Major Players
- Alnylam Pharmaceuticals, Inc.
- Calando Pharmaceuticals, Inc.
- Dharmacon, Inc.
- Dicerna Pharmaceuticals, Inc.
- Halo-Bio RNAi Therapeutics, Inc.
- Marina Biotech, Inc.
- OPKO Health, Inc.
- RXi Pharmaceuticals Corp.
- Sigma-Aldrich Co.
- B. Market Analytics
- Table 23: US Recent Past, Current & Future Analysis for RNA
Interference Market by Application Area - Drug Discovery and Target
Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart)
- Table 24: US Historic Review for RNA Interference Market by
Application Area - Drug Discovery and Target Validation, Reagents, and siRNA
Synthesis Independently Analyzed with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 25: US 15-Year Perspective for RNA Interference Market by
Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery
and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2010
& 2017(includes corresponding Graph/Chart)
13. CANADA
- A. Market Analysis
- Outlook
- Strategic Corporate Developments
- Tekmira Obtains New License for Alnylam' s InterfeRxtrade;
- Focus on Select Major Player
- Tekmira Pharmaceuticals Corporation
- B. Market Analytics
- Table 26: Canadian Recent Past, Current & Future Analysis for
RNA Interference Market by Application Area - Drug Discovery and Target
Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart)
- Table 27: Canadian Historic Review for RNA Interference Market by
Application Area - Drug Discovery and Target Validation, Reagents, and siRNA
Synthesis Independently Analyzed with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 28: Canadian 15-Year Perspective for RNA Interference Market
by Application Area - Percentage Breakdown of Dollar Sales for Drug
Discovery and Target Validation, Reagents, and siRNA Synthesis for Years
2003, 2010 & 2017(includes corresponding Graph/Chart)
14. JAPAN
- A. Market Analysis
- Outlook
- Strategic Corporate Developments
- Kyowa and Dicerna Expand Research Collaboration
- Quark to Collaborate with Nitto Denko
- Takeda and Alnylam Enter into Strategic Alliance
- B. Market Analytics
- Table 29: Japanese Recent Past, Current & Future Analysis for
RNA Interference Market by Application Area - Drug Discovery and Target
Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart)
- Table 30: Japanese Historic Review for RNA Interference Market by
Application Area - Drug Discovery and Target Validation, Reagents, and siRNA
Synthesis Independently Analyzed with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 31: Japanese 15-Year Perspective for RNA Interference Market
by Application Area - Percentage Breakdown of Dollar Sales for Drug
Discovery and Target Validation, Reagents, and siRNA Synthesis for Years
2003, 2010 & 2017 (includes corresponding Graph/Chart)
15. EUROPE
- A. Market Analysis
- B. Market Analytics
- Table 32: European Recent Past, Current & Future Analysis for
RNA Interference Market by Geographic Region - France, Germany, Italy, UK,
and Rest of Europe Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 33: European Historic Review for RNA Interference Market by
Geographic Region - France, Germany, Italy, UK, and Rest of Europe
Independently Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart)
- Table 34: European 15-Year Perspective for RNA Interference Market
by Geographic Region - Percentage Breakdown of Dollar Sales for France,
Germany, Italy, UK, and Rest of Europe for Years 2003, 2010 &
2017(includes corresponding Graph/Chart)
- Table 35: European Recent Past, Current & Future Analysis for
RNA Interference Market by Application Area - Drug Discovery and Target
Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart)
- Table 36: European Historic Review for RNA Interference Market by
Application Area - Drug Discovery and Target Validation, Reagents, and siRNA
Synthesis Independently Analyzed with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 37: European 15-Year Perspective for RNA Interference Market
by Application Area - Percentage Breakdown of Dollar Sales for Drug
Discovery and Target Validation, Reagents, and siRNA Synthesis for Years
2003, 2010 & 2017 (includes corresponding Graph/Chart)
15a. FRANCE
- A. Market Analysis
- Outlook
- Technological Innovations
- Polyplus-transfection Introduces jetPRIMEtrade; Transfection Reagent
- Strategic Corporate Developments
- Traversa and sanofi-aventis Ink Research Agreement
- Focus on Select Players
- Polyplus-transfection SA
- B. Market Analytics
- Table 38: French Recent Past, Current & Future Analysis for RNA
Interference Market by Application Area - Drug Discovery and Target
Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart)
- Table 39: French Historic Review for RNA Interference Market by
Application Area - Drug Discovery and Target Validation, Reagents, and siRNA
Synthesis Independently Analyzed with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 40: French 15-Year Perspective for RNA Interference Market by
Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery
and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2010
& 2017 (includes corresponding Graph/Chart)
15b. GERMANY
- A. Market Analysis
- Outlook
- Strategic Corporate Developments
- Cenix Receives R&D Grant from Saxony
- Marina Biotech Acquires Novosom' s SMARTICLES® Intellectual
Property Estate
- AstraZeneca and Cenix Extend Research Agreement on RNA Interference
- Cenix and Boehringer Ingelheim Ink Research Agreement
- B. Market Analytics
- Table 41: German Recent Past, Current & Future Analysis for RNA
Interference Market by Application Area - Drug Discovery and Target
Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017(includes
corresponding Graph/Chart)
- Table 42: German Historic Review for RNA Interference Market by
Application Area - Drug Discovery and Target Validation, Reagents, and siRNA
Synthesis Independently Analyzed with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 43: German 15-Year Perspective for RNA Interference Market by
Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery
and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2010
& 2017 (includes corresponding Graph/Chart)
15c. ITALY
- A. Market Analysis
- B. Market Analytics
- Table 44: Italian Recent Past, Current & Future Analysis for RNA
Interference Market by Application Area - Drug Discovery and Target
Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart)
- Table 45: Italian Historic Review for RNA Interference Market by
Application Area - Drug Discovery and Target Validation, Reagents, and siRNA
Synthesis Independently Analyzed with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 46: Italian 15-Year Perspective for RNA Interference Market by
Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery
and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2010
& 2017(includes corresponding Graph/Chart)
15d. THE UNITED KINGDOM
- A. Market Analysis
- Outlook
- Technological Innovations
- Tekmira, Alnylam, and UBC Co-Develop New Lipid Component
- AstraZeneca and Silence Therapeutics Extend R&D Alliance
- Intradigm and Silence Therapeutics Merge
- AstraZeneca and Cenix Extend Research Agreement on RNA Interference
- Focus on Select Player
- Silence Therapeutics
- B. Market Analytics
- Table 47: The UK Recent Past, Current & Future Analysis for RNA
Interference Market by Application Area - Drug Discovery and Target
Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart)
- Table 48: The UK Historic Review for RNA Interference Market by
Application Area - Drug Discovery and Target Validation, Reagents, and siRNA
Synthesis Independently Analyzed with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 49: The UK 15-Year Perspective for RNA Interference Market by
Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery
and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2010
& 2017 (includes corresponding Graph/Chart)
15e. REST OF EUROPE
- A. Market Analysis
- Outlook
- Strategic Corporate Developments
- Cenix to Establish New Subsidiary
- Tekmira Inks Agreement with Roche
- MDRNA Obtains Rights to RiboTask' s UNA Technology
- Roche Takes Over Mirus
- Focus on Select Players
- Devgen NV (Belgium)
- Exiqon A/S (Denmark)
- B. Market Analytics
- Table 50: Rest of European Recent Past, Current & Future
Analysis for RNA Interference Market by Application Area - Drug Discovery
and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart)
- Table 51: Rest of European Historic Review for RNA Interference
Market by Application Area - Drug Discovery and Target Validation, Reagents,
and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 52: Rest of European 15-Year Perspective for RNA Interference
Market by Application Area - Percentage Breakdown of Dollar Sales for Drug
Discovery and Target Validation, Reagents, and siRNA Synthesis for Years
2003, 2010 & 2017(includes corresponding Graph/Chart)
16. ASIA-PACIFIC
- A. Market Analysis
- Outlook
- Strategic Corporate Developments
- Sirnaomics Partners with a Chinese Firm for RNAi Therapeutics
Development
- Pfizer to Develop HCV Compounds of Tacere Therapeutics
- Benitec Collaborates with CCIA
- Allele Biotechnology Obtains Patent Approval for DNA-Encoded RNAi
- Focus on Select Players
- Benitec Limited (Australia)
- Bioneer Corporation (Korea)
- Genesis Research & Development Corporation Limited (New Zealand)
- B. Market Analytics
- Table 53: Asia-Pacific Recent Past, Current & Future Analysis
for RNA Interference Market by Application Area - Drug Discovery and Target
Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart)
- Table 54: Asia-Pacific Historic Review for RNA Interference Market
by Application Area - Drug Discovery and Target Validation, Reagents, and
siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 55: Asia-Pacific 15-Year Perspective for RNA Interference
Market by Application Area - Percentage Breakdown of Dollar Sales for Drug
Discovery and Target Validation, Reagents, and siRNA Synthesis for Years
2003, 2010 & 2017 (includes corresponding Graph/Chart)
17. REST OF WORLD
- A. Market Analysis
- B. Market Analytics
- Table 56: Rest of World Recent Past, Current & Future Analysis
for RNA Interference Market by Application Area - Drug Discovery and Target
Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart)
- Table 57: Rest of World Historic Review for RNA Interference Market
by Application Area - Drug Discovery and Target Validation, Reagents, and
siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 58: Rest of World 15-Year Perspective for RNA Interference
Market by Application Area - Percentage Breakdown of Dollar Sales for Drug
Discovery and Target Validation, Reagents, and siRNA Synthesis for Years
2003, 2010 & 2017 (includes corresponding Graph/Chart)
COMPETITIVE LANDSCAPE
|
 |
